MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF), a biotechnology company commercializing AI-driven voice technology for drug and alcohol intoxication detection, announced it has filed patent applications for its technology that uses voice and artificial intelligence (“AI”) to detect intoxication. The company said its Edge AI Intoxication Detection Kiosks use more than 50 million data points to predict drug and alcohol intoxication by analyzing the human voice, with commercial testing hardware and software solutions for the mining and aviation industries on track for delivery by the end of Q2 2026.
This development marks a significant step toward real-world deployment of voice-based intoxication detection in high-stakes industries. The technology, which leverages AI prediction models trained on a vast dataset, aims to provide a non-invasive and rapid method for screening individuals for impairment. According to the company, the system can predict alcohol intoxication with remarkable accuracy using only voice samples, potentially offering a safer alternative to traditional breathalyzer or blood tests in workplace settings.
The mining and aviation industries are particularly vulnerable to accidents caused by impaired workers, making reliable intoxication detection critical for safety. MindBio’s kiosks are designed to be deployed at entry points or check-in areas, allowing for quick and discreet screening. The patent filings cover both the hardware and software components of the system, including the AI algorithms that process voice data in real time.
“Our Edge AI Intoxication Detection Kiosks represent a paradigm shift in how industries can ensure workplace safety without invasive procedures,” said a company spokesperson. “By analyzing over 50 million data points, our AI can detect subtle changes in voice patterns associated with drug or alcohol use, providing results in seconds.”
The company is also exploring applications in law enforcement, construction, and other sectors where impairment poses significant risks. The technology’s ability to detect both alcohol and drug intoxication sets it apart from existing solutions, which typically focus on alcohol alone. MindBio’s approach could help address the growing problem of drug-impaired driving and workplace incidents.
For more information on the patent announcement, visit https://nnw.fm/mKvOu. Additional updates on MindBio Therapeutics are available in the company’s newsroom at https://nnw.fm/MBQIF.
